The ability to identify adverse cardiac effects is a crucial part of early drug development. CHDR offers an array of cardiac electrophysiology services, including comprehensive QT analyses and functional assays.


CHDR has been monitoring cardiac function for more than two decades. CHDR's Cardiology Services offers sponsors a ‘one-stop-shop’ for all cardiology needs. We have experience with measuring and imaging the microcirculation and can provide our sponsors with a range of macrovascular measurements.

Reliably measuring the QT interval

One of the most important issues to address when developing a new drug is its potential to alter cardiac electrical activity, in particular the duration of the ventricular action potential (i.e. the QT interval, or QTI). An increase in the QTI has been associated with sudden death due to ventricular arrhythmia, particularly torsade de pointes, a severe form of ventricular tachycardia. At CHDR, we have developed an innovative new method for measuring the QTI using ECG data. Providing a comprehensive assessment of a compound’s putative effect on the QTI is an essential step in clinical drug development and is now one of the core elements in our portfolio, offered as part of CHDR Cardiology Services®.

Cardiology Services

CHDR’s Cardiology Services® provides a wide range of cardiovascular diagnostic procedures to sponsors in the early stages of clinical drug development, including:

  • Dedicated QT-analyses
  • Holter recordings and analyses
  • Heart Rate Variability

CHDR Cardiology Services


  • Echocardiography
  • Cardiac MRI
  • Organ blood flow (kidney & liver)


  • Skin blood flow: speckle flow
  • Retinal blood velocity measurements (vein or artery)
Contact CHDR